ProtoKinetix, Inc. 10-K

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion provides information regarding the results of operations for the years ended December 31, 2025 and 2024, and our financial condition, liquidity and capital resources as of December 31, 2025 and 2024. The financial statements and the notes thereto contain detailed information that should be referred to in conjunction with this discussion. The following discussion and analysis should be read in conjunction with and our historical financial statements and the accompanying notes included elsewhere in this Annual Report on Form 10-K, as well as the Risk Factors and the Cautionary Note Regarding Forward-Looking Statements included above. Results of Operations For the Years Ended 2025 2024 Operating Expenses Amortization $ 51,292 $ 52,870 General and Administrative 58,135 61,470 Professional Fees 177,610 144,807 Research and Development 106,613 99,625 Share-Based Compensation — 5,416 Total operating expenses 393,650 364,188 Loss from Operations (393,650 ) (364,188 ) Net Loss $ (393,650 ) $ (364,188 ) 14 Revenues We had no revenues for the years ended December 31, 2025 and 2024. Gross profit and expenses The Company’s net loss was $393,650 for the year ending December 31, 2025 compared to $364,188 for the year ending December 31, 2024. These expenses were primarily incurred for professional fees, share-based compensation related to the operations of the Company’s business, research and development and other general and administrative expenses. Significant changes from the prior year include: • Professional fees increased by $32,804, year over year going to $177,610 from $144,806 as fees increased largely due to legal work for shareholder voting regarding increasing authorized shares of common stock, and legal work regarding valuation report of patent portfolio. • Share-based compensation decreased from $5,417 to $nil. The company did not issue share options as a form of compensation during the year ended 2025. • Research and development increased by $6,988 from $99,625 to $106,613 due to an increase in storage fees for the molecule inventory. The Company has scaled back on new research and moves toward leveraging the positive study findings. New projects will be targeted investments expanding the development of the AAGP ® molecule through institutional collaborations and industry partnerships. The Company is making a concentrated effort to find industry partners to move research forward. • General and administrative expenses pushed downward again year over year, changing by $3,335 from $61,470 to $58,135 due to the spending cuts in marketing, press releases and social media exposure. Majority of new information is currently released through updates to Company website. Our expenses in 2025 were $393,650 which included $177,610 in professional fees. We operate the Company by hiring outside consultants to assist us with management, strategic planning, organization and daily operations. These professional consulting services are related to marketing, accounting, merger opportunities as well as research development services. The Company also incurred total research and development expenses of $106,613 and general and administrative costs of $58,135 during the year ended December 31, 2025. Liquidity and Capital Resources As at December 31, 2025 2024 Cash $ 1,118 $ (4,697 ) Working Capital $ (183,266 ) $ (127,694 ) At December 31, 2025, we had $1,118 in cash and $2,168 in total current assets. As of December 31, 2025, we had a negative working capital equity deficit position of $183,266. Although as of the date of this Annual Report we do not believe we have sufficient capital to meet cash flow projections and carry forward our business objectives in the short-term, the Company will need additional working capital to continue its medical research or to be successful in any future business activities and continue to pay its liabilities. There can be no assurance that in the future we will be able to raise capital from outside sources in sufficient amounts to fund our business. The failure to secure adequate outside funding would have an adverse effect on our plan of operation and results therefrom and a corresponding negative impact on stockholder liquidity. 15 Sources and Uses of Cash for the Years ended December 31, 2025 and 2024 Net Cash Used in Operating Activities During the year ended December 31, 2025, net cash provided by operating activities decreased by $87,673 from a use of $223,050 to $135,377 provided for the years ended December 31, 2024 and 2025, respectively. This change was predominantly due to increase in accounts payable. Net Cash Used in Investing Activities During the year ended December 31, 2025, net cash used in investing activities decreased by $1,747 as we continue to maintain global patent applications. Current year spending was narrowed to maintenance of existing patent family. Net cash used for investing activities for the year ended December 31, 2024 was $58,055. Net cash used for investing activities for the year ended December 31, 2025 was $56,308. Net Cash Provided by Financing Activities During the year ended December 31, 2025, net cash provided by financing activities decreased by $58,500 from $256,000 to $197,500 for the years ended December 31, 2024 and 2025 respectively. This decrease was predominantly due to a reduction in funding of new research through private placement of common stock shares. Going Concern The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States (“U.S. GAAP”), which contemplate continuation of the Company as a going concern. The history of losses and the potential inability for the Company to make a profit from selling a good or service has raised substantial doubt about our ability to continue as a going concern. In spite of the fact that the current cash obligations of the Company are relatively minimal, given the cash position of the Company, we have very little cash to operate. We intend to fund the Company and attempt to meet corporate obligations by selling common stock. However, the Company’s common stock is at a low price and trading is not consistent. Off-Balance Sheet Arrangements None. Contractual Obligations As a smaller reporting company, we are not required to provide the information required by paragraph (a)(5) of this Item. Critical Accounting Policies The preparation of financial statements in conformity with U.S. GAAP requires management to make a variety of estimates and assumptions that affect (i) the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements, and (ii) the reported amounts of revenues and expenses during the reporting periods covered by the financial statements. Our management routinely makes judgments and estimates about the effect of matters that are inherently uncertain. As the number of variables and assumptions affecting the future resolution of the uncertainties increase, these judgments become even more subjective and complex. Although we believe that our estimates and assumptions are reasonable, actual results may differ significantly from these estimates. Changes in estimates and assumptions based upon actual results may have a material impact on our results of operation and/or financial condition. Our significant accounting policies are disclosed in Note 2 to the Financial Statements included in this Form 10-K. While all of the significant accounting policies are important to the Company’s financial statements, the following accounting policies and the estimates derived there from have been identified as being critical. 16 Share-Based Compensation The Company has granted warrants and options to purchase shares of the Company’s common stock to various parties for consulting services. The fair values of the warrants and options issued have been estimated using the Black-Scholes Option Pricing Model. The Company accounts for stock compensation with persons classified as employees for accounting purposes in accordance with ASC 718 “Compensation – Stock Compensation”, which recognizes awards at fair value on the date of grant and recognition of compensation over the service period for awards expected to vest. Cliff Vesting is used and awards vest on the last day of the vesting period. The fair value of stock options is determined using the Black-Scholes Option Pricing Model. The fair value of common shares issued for services is determined based on the Company’s stock price on the date of issuance. Share-based compensation for non-employees in exchange for goods and services used or consumed in an entity’s own operations are also recorded at fair value on the measurement date and accounted for in accordance with ASC 718. The measurement of share-based compensation is subject to periodic adjustment as the underlying instruments vest. The fair value of stock options is estimated using the Black-Scholes Option Pricing Model and the compensation charges are amortized over the vesting period. Intangible Assets – Patent and Patent Application Costs The Company owns intangible assets consisting of certain patents and patent applications. Intangible assets acquired separately are measured on initial recognition at cost. Following initial recognition, intangible assets are carried at cost less any accumulated amortization and any accumulated impairment losses. Subsequent expenditures are capitalized only when they increase the future economic benefits embodied in the specific asset to which they relate. The Company capitalizes its patent application costs. All other expenditures are recognized in profit or loss as incurred. As at December 31, 2025, the Company does not hold any intangible assets with indefinite lives. Intangible assets with finite lives are amortized over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortization method and amortization period of an intangible asset with a finite life is reviewed at least annually. Changes in the expected useful life or the expected pattern of consumption of future economic benefits embodied in the asset is accounted for by changing the amortization period or method, as appropriate, and are treated as changes in accounting estimates. Amortization is recognized in profit or loss on a straight-line basis over the estimated useful lives of the Company’s patents, whereas no amortization has been recognized on the not yet approved patent application costs for any new patents as at December 31, 2025. Sales and Marketing The Company is currently not selling or marketing any products. Inflation Although management expects that our operations will be influenced by general economic conditions, we do not believe that inflation had a material effect on our results of operations during the year ending December 31, 2025. ITEM 7A.  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK As a smaller reporting company, we are not required to provide the information required by this item. ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA The information required by this Item begins on page F-1 of this Annual Report on Form 10-K and is incorporated into this part by reference. 17 ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE None.